Tanaka I - Search Results

1

The current issues and future perspective of artificial intelligence for developing new treatment strategy in non-small cell lung cancer: harmonization of molecular cancer biology and artificial intelligence.

Tanaka I, Furukawa T, Morise M. Tanaka I, et al. Cancer Cell Int. 2021 Aug 26;21(1):454. doi: 10.1186/s12935-021-02165-7. Cancer Cell Int. 2021. PMID: 34446006 Free PMC article. Review.

2

A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting.

Tanaka I, Kawada K, Morise M, Hase T, Hayashi H, Sokai A, Fukatsu A, Kondo M, Nomura F, Hasegawa Y. Tanaka I, et al. Cancer Chemother Pharmacol. 2018 Feb;81(2):339-345. doi: 10.1007/s00280-017-3497-0. Epub 2017 Dec 12. Cancer Chemother Pharmacol. 2018. PMID: 29234921 Clinical Trial.

3

eIF2β, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer.

Tanaka I, Sato M, Kato T, Goto D, Kakumu T, Miyazawa A, Yogo N, Hase T, Morise M, Sekido Y, Girard L, Minna JD, Byers LA, Heymach JV, Coombes KR, Kondo M, Hasegawa Y. Tanaka I, et al. Cancer Sci. 2018 Jun;109(6):1843-1852. doi: 10.1111/cas.13602. Epub 2018 May 25. Cancer Sci. 2018. PMID: 29624814 Free PMC article.

4

An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.

Sato M, Matsui A, Shimoyama Y, Omote N, Morise M, Hase T, Tanaka I, Suzuki K, Hasegawa Y. Sato M, et al. Among authors: tanaka i. Intern Med. 2018 Dec 1;57(23):3429-3432. doi: 10.2169/internalmedicine.0999-18. Epub 2018 Aug 10. Intern Med. 2018. PMID: 30101911 Free PMC article.

5

Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations.

Tanaka I, Morise M, Kodama Y, Matsui A, Ozawa N, Ozone S, Goto D, Miyazawa A, Hase T, Hashimoto N, Sato M, Hasegawa Y. Tanaka I, et al. Lung Cancer. 2019 Jan;127:169-171. doi: 10.1016/j.lungcan.2018.11.018. Epub 2018 Nov 14. Lung Cancer. 2019. PMID: 30477806 No abstract available.

6

Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer Patients With EGFR Mutation.

Tanaka I, Morise M, Miyazawa A, Kodama Y, Tamiya Y, Gen S, Matsui A, Hase T, Hashimoto N, Sato M, Hasegawa Y. Tanaka I, et al. Clin Lung Cancer. 2020 May;21(3):273-280.e4. doi: 10.1016/j.cllc.2020.01.011. Epub 2020 Jan 27. Clin Lung Cancer. 2020. PMID: 32088115

7

UHRF1, a Regulator of Methylation, as a Diagnostic and Prognostic Marker for Lung Cancer.

Goto D, Komeda K, Uwatoko N, Nakashima M, Koike M, Kawai K, Kodama Y, Miyazawa A, Tanaka I, Hase T, Morise M, Hasegawa Y, Kawabe T, Sato M. Goto D, et al. Among authors: tanaka i. Cancer Invest. 2020 Apr;38(4):240-249. doi: 10.1080/07357907.2020.1747483. Epub 2020 Apr 16. Cancer Invest. 2020. PMID: 32212938

8

Primary Prophylaxis Indication for Docetaxel Induced Febrile Neutropenia in Elderly Patients with Non-Small Cell Lung Cancer.

Matsui A, Morise M, Tanaka I, Ozone S, Matsuzawa R, Koyama J, Hase T, Hashimoto N, Sato M, Hasegawa Y. Matsui A, et al. Among authors: tanaka i. Cancer Invest. 2020 Aug;38(7):424-430. doi: 10.1080/07357907.2020.1793350. Epub 2020 Jul 30. Cancer Invest. 2020. PMID: 32643445

9

Efficacies of programmed cell death 1 ligand 1 blockade in non-small cell lung cancer patients with acquired resistance to prior programmed cell death 1 inhibitor and development of diabetic ketoacidosis caused by two different etiologies: a retrospective case series.

Ishi A, Tanaka I, Iwama S, Sakakibara T, Mastui T, Kobayashi T, Hase T, Morise M, Sato M, Arima H, Hashimoto N. Ishi A, et al. Among authors: tanaka i. Endocr J. 2021 May 28;68(5):613-620. doi: 10.1507/endocrj.EJ20-0769. Epub 2021 May 1. Endocr J. 2021. PMID: 33790087 Free article.

10

Oxytocin receptor is a promising therapeutic target of malignant mesothelioma.

Kodama Y, Tanaka I, Sato T, Hori K, Gen S, Morise M, Matsubara D, Sato M, Sekido Y, Hashimoto N. Kodama Y, et al. Among authors: tanaka i. Cancer Sci. 2021 Sep;112(9):3520-3532. doi: 10.1111/cas.15025. Epub 2021 Jul 4. Cancer Sci. 2021. PMID: 34115916 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,406 results

Search Page